Breast Cancer Statistics in Korea, 2019
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Jung Eun | - |
dc.contributor.author | Kim, Zisun | - |
dc.contributor.author | Park, Chan Sub | - |
dc.contributor.author | Park, Eun Hwa | - |
dc.contributor.author | Lee, Sae Byul | - |
dc.contributor.author | Lee, Se Kyung | - |
dc.contributor.author | Choi, Young Jin | - |
dc.contributor.author | Han, Jaihong | - |
dc.contributor.author | Jung, Kyu-Won | - |
dc.contributor.author | Kim, Hee Jeong | - |
dc.contributor.author | Kim, Hyun-Ah | - |
dc.date.accessioned | 2023-12-13T20:01:17Z | - |
dc.date.available | 2023-12-13T20:01:17Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.issn | 1738-6756 | - |
dc.identifier.issn | 2092-9900 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25085 | - |
dc.description.abstract | This article provides an annual update of Korean breast cancer statistics, including the incidence, tumor stage, type of surgical treatment, and mortality. The data was collected from the Korean Breast Cancer Society registry system and Korean Central Cancer Registry. In 2019, 29,729 women were newly diagnosed with breast cancer. Breast cancer has continued to increase in incidence since 2002 and been the most common cancer in Korean women since 2019. Of the newly diagnosed cases in 2019, 24,820 (83.5%) were of invasive carcinomas, and 4,909 (16.5%) were of carcinoma in situ. The median age of women with breast cancer was 52.8 years, and breast cancer was most commonly diagnosed in the age group of 40-49 years. The number of patients who have undergone breast conserving surgery has continued to increase since 2016, with 68.6% of patients undergoing breast conserving surgery in 2019. The incidence of early-stage breast cancer continues to increase, with stage 0 or I breast cancer accounting for 61.6% of cases. The most common subtype of breast cancer is the hormone receptor-positive human epidermal growth factor receptor 2-negative subtype (63.1%). The 5-year relative survival rate of patients with breast cancer from 2015 to 2019 was 93.6%, with an increase of 14.3% compared to that from 1993 to 1995. This report improves our understanding of breast cancer characteristics in South Korea. | - |
dc.format.extent | 14 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 한국유방암학회 | - |
dc.title | Breast Cancer Statistics in Korea, 2019 | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4048/jbc.2023.26.e27 | - |
dc.identifier.scopusid | 2-s2.0-85170522110 | - |
dc.identifier.wosid | 001024464800001 | - |
dc.identifier.bibliographicCitation | Journal of Breast Cancer, v.26, no.3, pp 207 - 220 | - |
dc.citation.title | Journal of Breast Cancer | - |
dc.citation.volume | 26 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 207 | - |
dc.citation.endPage | 220 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002972825 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | BODY-MASS INDEX | - |
dc.subject.keywordPlus | HETEROGENEITY | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordAuthor | Breast Neoplasms | - |
dc.subject.keywordAuthor | Epidemiology | - |
dc.subject.keywordAuthor | Incidence | - |
dc.subject.keywordAuthor | Registries | - |
dc.subject.keywordAuthor | Republic of Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.